Amorphous-Amorphous Phase Separation in API/Polymer Formulations
AbstractThe long-term stability of pharmaceutical formulations of poorly-soluble drugs in polymers determines their bioavailability and therapeutic applicability. However, these formulations do not only often tend to crystallize during storage, but also tend to undergo unwanted amorphous-amorphous phase separations (APS). Whereas the crystallization behavior of APIs in polymers has been measured and modeled during the last years, the APS phenomenon is still poorly understood. In this study, the crystallization behavior, APS, and glass-transition temperatures formulations of ibuprofen and felodipine in polymeric PLGA excipients exhibiting different ratios of lactic acid and glycolic acid monomers in the PLGA chain were investigated by means of hot-stage microscopy and DSC. APS and recrystallization was observed in ibuprofen/PLGA formulations, while only recrystallization occurred in felodipine/PLGA formulations. Based on a successful modeling of the crystallization behavior using the Perturbed-Chain Statistical Associating Fluid Theory (PC-SAFT), the occurrence of APS was predicted in agreement with experimental findings. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 131 KB)
Share & Cite This Article
Luebbert, C.; Huxoll, F.; Sadowski, G. Amorphous-Amorphous Phase Separation in API/Polymer Formulations. Molecules 2017, 22, 296.
Luebbert C, Huxoll F, Sadowski G. Amorphous-Amorphous Phase Separation in API/Polymer Formulations. Molecules. 2017; 22(2):296.Chicago/Turabian Style
Luebbert, Christian; Huxoll, Fabian; Sadowski, Gabriele. 2017. "Amorphous-Amorphous Phase Separation in API/Polymer Formulations." Molecules 22, no. 2: 296.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.